Scarica l'app Stockscreener
26.62
1.22%
0.32
Pre-mercato:
26.23
-0.39
-1.47%
Precedente Chiudi:
$26.30
Aprire:
$26.53
Volume 24 ore:
916.42K
Relative Volume:
1.33
Capitalizzazione di mercato:
$2.03B
Reddito:
-
Utile/perdita netta:
$-64.16M
Rapporto P/E:
-20.96
EPS:
-1.2702
Flusso di cassa netto:
$-69.06M
1 W Prestazione:
-0.78%
1M Prestazione:
-4.93%
6M Prestazione:
-23.57%
1 anno Prestazione:
-25.37%
Intervallo 1D:
$26.32
$27.05
Intervallo di 1 settimana:
$25.48
$28.08
Portata 52W:
$24.16
$46.99
Cg Oncology Inc Stock (CGON) Company Profile
Nome
Cg Oncology Inc
Settore
Industria
Telefono
(949) 419-6203
Indirizzo
400 SPECTRUM CENTER DRIVE, IRVINE
Confronta CGON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.62 | 2.03B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2024-06-28 | Iniziato | BofA Securities | Buy |
| 2024-02-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Iniziato | Goldman | Neutral |
| 2024-02-20 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-14 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cg Oncology Inc Borsa (CGON) Ultime notizie
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates - The Manila Times
CG Oncology to Present Late-Breaking Abstract and Key Research on Cretostimogene Grenadenorepvec at 40th Annual EAU Congress - Nasdaq
Major Clinical Trial Results: CG Oncology Unveils New Bladder Cancer Treatment Data at European Congress - StockTitan
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Morgan Stanley - Defense World
3 Analysts Assess CG Oncology: What You Need To Know - Benzinga
Oncolytic Adenovirus Market Set to Grow Substantially Through 2032, DelveInsight Projects | CG Oncology, Orca Therapeutics B.V., Syneos Health, DNAtrix, Inc. - Barchart
Oncolytic Adenovirus Market Set to Grow Substantially Through - openPR
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - Benzinga
New York State Common Retirement Fund Grows Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Cg Oncology Inc (CGON) is looking forward to a strong quarter - SETE News
CG Oncology stock hits 52-week low at $24.15 amid challenges - Investing.com India
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Rhumbline Advisers - Defense World
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can CG Oncology's CEO Presentation Reveal New Bladder Cancer Treatment Progress? - StockTitan
CG Oncology Enters Oversold Territory (CGON) - Nasdaq
CG Oncology stock hits 52-week low at $25.71 amid challenges - Investing.com Canada
Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? - Insider Monkey
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025 - Citeline News & Insights
Critical Analysis: Novozymes A/S (OTCMKTS:NVZMY) vs. CG Oncology (NASDAQ:CGON) - Defense World
Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Valneva (NASDAQ:VALN) and CG Oncology (NASDAQ:CGON) Head-To-Head Review - Defense World
UroGen Plots Expansion, Brings In A New Asset - Citeline News & Insights
Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Buy” by Analysts - Defense World
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Mirae Asset Global Investments Co. Ltd. Buys Shares of 2,254 CG Oncology, Inc. (NASDAQ:CGON) - Defense World
China Universal Asset Management Co. Ltd. Acquires New Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Market Watch Highlights: Cg Oncology Inc (CGON) Ends on an Upturn Note at 30.32 - The Dwinnex
CGON Stock Sees Surge of Approximately 0.10% in Last Five Days - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62% - Yahoo Finance
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
CG Oncology, Inc. (NASDAQ:CGON) Stock Holdings Boosted by JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Analysts Offer Predictions for CG Oncology FY2025 Earnings - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cantor Fitzgerald Comments on CG Oncology FY2025 Earnings - MarketBeat
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
This CG Oncology Insider Reduced Their Stake By 16% - Simply Wall St
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? - MSN
Cg Oncology Inc (CGON) Volatility Hits 4.53%: What Good Investors Need To Be Aware Of - Stocks Register
Cg oncology director Leonard Post sells shares worth $29,660 By Investing.com - Investing.com Australia
Cg oncology director Leonard Post sells shares worth $29,660 - Investing.com India
CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares - MarketBeat
Cg Oncology Inc Azioni (CGON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):